Blue Faery: The Adrienne Wilson Liver Cancer Association

11/02/2026

Transplant Oncology Expands Liver Transplant Options

For patients with hepatocellular carcinoma (HCC), perfusion beyond tumor margin on contrast-enhanced ultrasound that exceeds gray-scale ultrasound tumor measurement by 5 mm is associated with a 76 percent higher risk of worse recurrence-free survival, according to newly published research.

New research suggests that perfusion beyond margin (PBM) for hepatocellular carcinoma (HCC) tumors on contrast-enhanced ultrasound (CEUS) is associated with significantly worse local tumor progression-free survival, more than double the rate of microvascular invasion and worse overall recurrence-free survival. https://vist.ly/5r363

For patients with hepatocellular carcinoma (HCC), perfusion beyond tumor margin on contrast-enhanced ultrasound that exceeds gray-scale ultrasound tumor measurement by 5 mm is associated with a 76 percent higher risk of worse recurrence-free survival, according to newly published research.

10/30/2026

Biosimilar-Backed Triplet Regimen Shows Feasibility in Heavily Pretreated Liver Cancer

For people with advanced hepatocellular carcinoma whose disease has progressed despite prior immunotherapy, treatment options have remained limited and largely empirical. New findings from the phase 2 ReUNION-1 trial suggested that integrating stereotactic body radiotherapy (SBRT) with continued immune checkpoint inhibition and a bevacizumab biosimilar may offer a strategy to overcome resistance while maintaining an acceptable safety profile.

The open-label, single-arm ReUNION-1 study, published in Nature Communications, evaluated SBRT followed by sintilimab (a PD-1 inhibitor) plus a bevacizumab biosimilar in people with unresectable hepatocellular carcinoma (HCC) whose disease had progressed after at least one prior anti–PD-1–based regimen. Immune checkpoint inhibitor resistance remains a substantial challenge in HCC, where objective response rates to monotherapy have historically ranged from 13% to 20%, and where second-line standards have largely been extrapolated from sorafenib-pretreated populations. https://vist.ly/5qq4j

A phase 2 trial showed that combining targeted radiotherapy with PD-1 blockade and a bevacizumab biosimilar can elicit responses in advanced liver cancer.

10/29/2026

💙 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗱𝗼𝗲𝘀𝗻'𝘁 𝗲𝗻𝗱 𝘄𝗶𝘁𝗵 𝗢𝗰𝘁𝗼𝗯𝗲𝗿. 𝗡𝗲𝗶𝘁𝗵𝗲𝗿 𝗱𝗼𝗲𝘀 𝗵𝗼𝗽𝗲.

As Liver Cancer Awareness Month comes to a close, our commitment to patients and families continues.

Every day, people affected by liver cancer need trusted information, meaningful connections, and the reassurance that they don't have to face their journey alone.

At Blue Faery, that work continues all year long. And with your support, so can our impact.

💙 𝗛𝗲𝗹𝗽 𝘂𝘀 𝘁𝘂𝗿𝗻 𝗮𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗶𝗻𝘁𝗼 𝗹𝗮𝘀𝘁𝗶𝗻𝗴 𝘀𝘂𝗽𝗽𝗼𝗿𝘁. 𝗠𝗮𝗸𝗲 𝗮 𝗴𝗶𝗳𝘁 𝘁𝗼𝗱𝗮𝘆: https://vist.ly/5qj4p

10/28/2026

Biomarkers Indicating Higher Liver Cancer Risk In Chronic Hepatitis B Patients Identified

Chronic hepatitis B is a viral disease that affects the liver and greatly increases the risks of liver cirrhosis and hepatocellular cancer (HCC, liver cancer). It affects approximately 296 million people worldwide. Hepatitis B is treatable; with the advent of nucleoside (nucleotide) analog (NA) therapy, viral replication is suppressed, reducing the risk of disease progression.

NA therapy results in partial cures (undetectable viral DNA but detectable viral antigen levels) in most cases, and, rarely, functional cures (undetectable viral DNA and antigen levels). However, due to the biology of the hepatitis B virus, the development of HCC cannot completely be prevented, even in the rare cases of functional cures.

Researchers at Gifu Kyoritsu University and Hiroshima University examined the use of novel biomarkers to accurately determine HCC risk. Specifically, they showed that hepatitis B viral RNA (HBV RNA) is better for this purpose compared to both currently used biomarkers as well as other proposed biomarkers. Hiroshima University https://vist.ly/5qdw2

Researchers at Hiroshima University and Gifu Kyoritsu University identified Hepatitis B RNA serum levels as a biomarker that more accurately stratifies risk of liver cancer in individuals who have been functionally cured of chronic hepatitis B.

10/27/2026

iMBIs Support Patients With HCC, But Resistance to Mindfulness Practice May Persist

Patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE) often experience significant psychological distress due to the disease’s high mortality rate. However, although internet-based mindfulness-based interventions (iMBIs) have some limitations, they can provide these patients some benefit. These findings were reported in the Journal of Medical Internet Research.

A research team conducted a study with a qualitative descriptive design to learn more about these patients’ experiences with iMBIs and the acceptability and applicability of these interventions. The study employed semistructured personal interviews. The study included 11 patients with HCC who had undergone TACE and participated in tailored iMBIs over a 2-year period. https://vist.ly/5q88r

10/26/2026

Evaluating The Clinical Utility Of MRI In Liver Cancer Planning And Simulation

Accurate imaging is essential in liver cancer radiation therapy, where precise target definition directly impacts treatment safety and effectiveness. CT remains the standard for simulation and planning, but its limited soft-tissue contrast can hinder tumor delineation, particularly in a dense area of organs at risk and opportunity for tumor motion. MRI overcomes these limitations with superior soft-tissue contrast, improved lesion detection, and the ability to assess and characterize motion of both tumors and adjacent organs at risk. These advantages make MRI a powerful complement or alternative to CT, supporting more accurate gross tumor volume (GTV) definition and greater confidence in treatment planning. https://vist.ly/5p2uh

Accurate imaging is essential in liver cancer radiation therapy, where precise target definition directly impacts treatment safety and effectiveness. CT remains the standard for simulation and planning, but its limited soft-tissue contrast can hinder tumor delineation, particularly in a dense area o...

10/24/2026

A Liver Cancer Journey Marked by Persistence, Family and Hope

For many patients, the path to a liver cancer diagnosis is not straightforward. Symptoms can be vague, tests inconclusive and reassurance misleading. In a recent CURE conversation, Charles Walker shared how months of unexplained fatigue and back pain ultimately led to a life-altering diagnosis.

Walker, a lifelong athlete and father of three, initially believed his active lifestyle protected him from serious illness. However, in May 2023, routine symptoms escalated into something he could not ignore. After visits with chiropractors, pain specialists and other providers failed to provide answers, a pulmonology appointment finally revealed the cause: hepatocellular carcinoma (HCC), driven by years of undiagnosed metabolic dysfunction–associated steatotic liver disease. CURE Today
https://vist.ly/5ptw5

In a recent CURE conversation, Charles Walker shared how months of unexplained fatigue and back pain ultimately led to a life-altering diagnosis.

10/23/2026

✈️💙 We're on our way, Chicago!

The Blue Faery team is headed to the Windy City for our FREE HCC Lunch & Learn this Saturday, October 24!

We're excited to connect with patients, caregivers, advocates, and healthcare professionals for a day of learning, support, and community at UChicago Medicine.

There's still time to join us!

🔗 Register for free: https://vist.ly/5pq4r

10/22/2026

🎙️ 𝗟𝗜𝗩𝗘 𝘁𝗼𝗱𝗮𝘆: 𝗬𝗼𝘂𝗿 𝗟𝗶𝘃𝗲𝗿 𝗜𝘀 𝗧𝗮𝗹𝗸𝗶𝗻𝗴. 𝗔𝗿𝗲 𝗬𝗼𝘂 𝗟𝗶𝘀𝘁𝗲𝗻𝗶𝗻𝗴?

Blue Faery Founder and President 𝗔𝗻𝗱𝗿𝗲𝗮 𝗪𝗶𝗹𝘀𝗼𝗻 𝗪𝗼𝗼𝗱𝘀 joins Taste Life Nutrition today, October 22, at 10 a.m. MT / 12 p.m. ET for a conversation about liver health, prevention, advocacy, and the importance of asking better questions.

𝗧𝗵𝗲𝘆'𝗹𝗹 𝗱𝗶𝘀𝗰𝘂𝘀𝘀:

🔹 Risk factors for liver disease and liver cancer
🔹 What routine labs may reveal—and what they may miss
🔹 Why early detection matters
🔹 How informed conversations with your healthcare provider can make a difference
🔹 Emerging research shaping the future of liver health

🎧 𝗪𝗮𝘁𝗰𝗵 𝗹𝗶𝘃𝗲 𝗼𝗻 𝘁𝗵𝗲 𝗧𝗮𝘀𝘁𝗲 𝗟𝗶𝗳𝗲 𝗡𝘂𝘁𝗿𝗶𝘁𝗶𝗼𝗻 𝗙𝗮𝗰𝗲𝗯𝗼𝗼𝗸 𝗽𝗮𝗴𝗲:
https://vist.ly/5piui

𝗬𝗼𝘂 𝗰𝗮𝗻 𝗮𝗹𝘀𝗼 𝗹𝗶𝘀𝘁𝗲𝗻 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗞𝗨𝗛𝗦 𝗗𝗲𝗻𝘃𝗲𝗿:
https://vist.ly/5piuj

Tune in today and share this conversation with someone who could benefit from learning more about liver health.

10/21/2026

ABK Biomedical Completes Enrollment in ROUTE90 Pivotal Study for Primary Liver Cancer

ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic medical devices, today announced the completion of patient enrollment in its pivotal U.S. FDA Investigational Device Exemption (IDE) study, ROUTE90. The study evaluates Eye90 microspheres®, a novel Yttrium-90 (Y90) radioembolization device, for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer.

Eye90 microspheres, previously granted FDA Breakthrough Device Designation, are designed to treat unresectable liver tumors with enhanced control, visualization, and personalized dosimetry (defined as dose targeted for day of treatment without decay and based on individual patient and tumor anatomy). https://vist.ly/5pdhs